S D Pharmaceuticals

S D Pharmaceuticals is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1991, the company is headquartered in Muzaffarnagar, Uttar Pradesh, India. It is registered under the Corporate Identification Number (CIN) U24231UP1991PTC012999. The authorized capital is ₹1.5 million, with a paid-up capital of ₹1.18 million. The company's last Annual General Meeting (AGM) was held on 30 September 2011, and the balance sheet was filed on 31 March 2011.

S D Pharmaceuticals operates manufacturing facilities in Muzaffarnagar, Uttar Pradesh, India. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and certifications are not publicly available.

The company's leadership includes Managing Director Rajender Kumar, who has been in this role since 16 December 1992, and Director Partibha Goyal, appointed on 1 April 2002. Both have been associated with the company for several decades, contributing to its strategic direction and operations.

S D Pharmaceuticals' export data indicates shipments to various countries, including Venezuela, Iran, the United Arab Emirates, and others. However, specific regulatory approvals or market access statuses in the US, EU, UK, Australia, and Japan are not publicly disclosed. The company's focus appears to be on markets in Latin America, the Middle East, and Africa.

The company's export data highlights significant shipments to countries in Latin America, such as Venezuela and Nicaragua, as well as to the Middle East, including Iran and Iraq. These regions are emerging markets for S D Pharmaceuticals, indicating a strategic focus on expanding its presence in these areas.

S D Pharmaceuticals demonstrates a concentrated export strategy, with a significant portion of its shipments directed towards Latin American and Middle Eastern countries. This focus suggests a deliberate approach to penetrate and establish a foothold in these emerging markets. The company's portfolio concentration, with the top five products accounting for 95.6% of total export value, indicates a strategic emphasis on a select range of products.

Specific details regarding S D Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no market presence in the U.S.

There is no publicly available information regarding S D Pharmaceuticals' compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's export data does not provide insights into these certifications.

S D Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not provide information on these regulatory aspects.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to S D Pharmaceuticals. The company's export data does not indicate any regulatory actions or compliance issues.

S D Pharmaceuticals operates in a competitive landscape with numerous pharmaceutical exporters from India. While specific competitors in overlapping categories are not identified, the company's focus on select therapeutic categories and emerging markets positions it uniquely. The portfolio concentration, with the top five products accounting for 95.6% of total export value, suggests a strategic emphasis on a narrow product range, which may influence its competitive positioning.

S D Pharmaceuticals' key differentiators include its strategic focus on emerging markets in Latin America and the Middle East, as evidenced by its export data. The company's concentrated product portfolio, with the top five products accounting for 95.6% of total export value, indicates a specialized approach to product offerings. However, the lack of publicly available information on regulatory certifications and approvals may impact its competitive advantages.

S D Pharmaceuticals appears to be strategically positioned as a specialized exporter focusing on select therapeutic categories and emerging markets. The company's export data indicates a deliberate approach to penetrate and establish a presence in regions such as Latin America and the Middle East. The concentrated product portfolio suggests a focus on specific products, which may influence its strategic direction in the global pharmaceutical market.

S D Pharmaceuticals has demonstrated a consistent export track record, with a total export value of $754,000 USD across 35 shipments from 2022 to 2026. The company's export data indicates shipments to 153 buyers, primarily in Latin America and the Middle East, suggesting a reliable supply chain and customer base. However, the lack of publicly available information on regulatory certifications and approvals may require further due diligence for potential partners.

Importers should verify the following certifications when considering S D Pharmaceuticals as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

• WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practice standards to ensure product quality and safety.

• EU GMP Certification: Confirm adherence to European Union Good Manufacturing Practice standards, which are recognized globally for quality assurance.

• ISO Certification: Check for International Organization for Standardization certifications, which indicate adherence to international quality management standards.

To verify these certifications, importers can request copies of the certificates directly from S D Pharmaceuticals, consult the respective regulatory bodies' official websites, or engage third-party verification services.

When conducting due diligence on S D Pharmaceuticals, consider the following steps:

• Regulatory Compliance: Verify the company's compliance with relevant regulatory bodies, including the FDA, WHO, EU GMP, and ISO standards.

• Financial Stability: Review the company's financial statements and credit history to assess financial health and stability.

• Product Quality: Request product samples and conduct quality assessments to ensure they meet required standards.

• Supply Chain Reliability: Evaluate the company's supply chain processes and logistics capabilities to ensure timely and consistent delivery.

• References and Reputation: Seek references from existing clients and assess the company's reputation in the industry.

Red flags to watch for include a lack of transparency in operations, unresolved regulatory issues, inconsistent product quality, and financial instability. Recommended pre-order checks involve verifying certifications, assessing financial health, and conducting quality assessments to ensure the company's products meet required standards.